European pharmaceutical trade with the US remains critical despite tariff turbulence. New drugs and lucrative US markets are key for Europe's pharmaceutical sector[original content]. Exports of pharmaceutical products from the EU to the US reached EUR 84.4 billion (USD 98.1 billion) during the first three quarters of last year, the largest export category according to Eurostat[1]. The US is the country where new medicines are most often introduced to the market first – 110 new active substances from 2020 to 2024 are still unavailable in Europe[2]. European companies respond to the 15 percent tariff by shifting billions of investments to research and development in the US[2]. Governments are moving towards closer trade with Asia, while the US leads in innovative medicines, particularly in oncology, neurology and gene therapy[2]. The pharmaceutical sector is among the most threatened by US tariffs, along with automotive and aviation[4].